Affinity Asset Advisors
$2.0B 13F equity value
108 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Affinity Asset Advisors covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| ROIV | ROIVANT SCIENCES LTD | 3,750,000 | $133M | 6.6% |
| APGE | APOGEE THERAPEUTICS INC | 987,000 | $131M | 6.5% |
| SYRE | SPYRE THERAPEUTICS INC | 1,279,134 | $114M | 5.6% |
| XENE | XENON PHARMACEUTICALS INC | 1,595,000 | $96M | 4.8% |
| ERAS | ERASCA INC | 5,250,000 | $96M | 4.8% |
| INSM | INSMED INC | 650,000 | $69M | 3.4% |
| PRAX | PRAXIS PRECISION MEDICINES I | 185,000 | $62M | 3.1% |
| ALKS | ALKERMES PLC | 1,125,000 | $59M | 2.9% |
| ORKA | ORUKA THERAPEUTICS INC | 590,000 | $56M | 2.8% |
| ANAB | ANAPTYSBIO INC | 826,109 | $56M | 2.8% |
Track Affinity Asset Advisors's 13F portfolio: $2.0B in reported holdings, 108 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}